Literature DB >> 34697667

Antiproliferatives and Transplantation.

Robert Donovan1, Howard Eisen1, Omaima Ali2.   

Abstract

Antiproliferative agents include Mycophenolic acid and Azathioprine (which is less commonly used unless in certain conditions). They were initially identified for use in autoimmune and cancer research due to their role in disruption of cellular replication. They have now become the cornerstone of antirejection maintenance therapy in solid organ transplant. In this chapter we will describe the major times that lead to discovery, mechanisms of action, side effects, use during pregnancy and the major clinical trials.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Antiproliferatives; Azathioprine; Clinical trials; Discovery; Mechanism of action; Mycophenolic acid; Side effects

Mesh:

Substances:

Year:  2022        PMID: 34697667     DOI: 10.1007/164_2021_556

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  26 in total

1.  A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.

Authors:  L Fischer; M Sterneck; C G Gahlemann; M Malago; X Rogiers; C E Broelsch
Journal:  Transplant Proc       Date:  2000-11       Impact factor: 1.066

2.  The metabolism of 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in man.

Authors:  G B ELION; S W CALLAHAN; G H HITCHINGS; R W RUNDLES
Journal:  Cancer Chemother Rep       Date:  1960-07

Review 3.  Therapeutic monitoring of mycophenolate mofetil.

Authors:  Hyunyoung Jeong; Bruce Kaplan
Journal:  Clin J Am Soc Nephrol       Date:  2006-11-08       Impact factor: 8.237

4.  Mycophenolate mofetil monitoring: is there evidence that it can improve outcomes?

Authors:  R Byrne; S E Yost; B Kaplan
Journal:  Clin Pharmacol Ther       Date:  2011-08       Impact factor: 6.875

5.  Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.

Authors:  H J Eisen; J Kobashigawa; R C Starling; D F Pauly; A Kfoury; H Ross; S-S Wang; B Cantin; A Van Bakel; G Ewald; S Hirt; H Lehmkuhl; A Keogh; M Rinaldi; L Potena; A Zuckermann; G Dong; C Cornu-Artis; P Lopez
Journal:  Am J Transplant       Date:  2013-02-22       Impact factor: 8.086

6.  Regulation of the interaction of inosine monophosphate dehydrogenase with mycophenolic Acid by GTP.

Authors:  YanShan Ji; Jingjin Gu; Alexander M Makhov; Jack D Griffith; Beverly S Mitchell
Journal:  J Biol Chem       Date:  2005-10-21       Impact factor: 5.157

7.  A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial.

Authors:  David A Baran; Mark J Zucker; Luis H Arroyo; Margarita Camacho; Marc E Goldschmidt; Stephen J Nicholls; Jeanne Prevost-Fernandez; Candace Carr; Laura Adams; Susan Pardi; Vera Hou; Maria Binetti; Jeanine McCahill; Joanne Chichetti; Valerie Viloria; Mary Gladys Sanagustin; Jennifer Ebuenga-Smith; Leslie Mele; Anthony Martin; Donna Blicharz; Kathy Wolski; Ludmilla Olesnicky; Fang Qian; Alan L Gass; Marc Cohen
Journal:  Circ Heart Fail       Date:  2011-01-07       Impact factor: 8.790

8.  Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.

Authors:  Thomas Gonwa; Robert Mendez; Harold C Yang; Samuel Weinstein; Stephen Jensik; Steven Steinberg
Journal:  Transplantation       Date:  2003-04-27       Impact factor: 4.939

9.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

Authors:  Howard J Eisen; E Murat Tuzcu; Richard Dorent; Jon Kobashigawa; Donna Mancini; Hannah A Valantine-von Kaeppler; Randall C Starling; Keld Sørensen; Manfred Hummel; Joan M Lind; Kamal H Abeywickrama; Peter Bernhardt
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

10.  Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.

Authors:  A K Andreassen; B Andersson; F Gustafsson; H Eiskjaer; G Rådegran; E Gude; K Jansson; D Solbu; K Karason; S Arora; G Dellgren; L Gullestad
Journal:  Am J Transplant       Date:  2016-01-28       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.